[1]惠权斌,陈永刚△,陈 盼.丹参川芎嗪注射液联合替格瑞洛用药时机对急性心肌梗死治疗效果的影响研究[J].陕西医学杂志,2020,49(7):866-870.[doi:DOI:10.3969/j.issn.10007377.2020.07.027]
　HUI Quanbin,CHEN Yonggang,CHEN Pan..The timing of salviae miltiorrhizae and ligustrazine hydrochloride injection combined with ticagrelor on therapeutic effect of acute myocardial infarction[J].,2020,49(7):866-870.[doi:DOI:10.3969/j.issn.10007377.2020.07.027]
点击复制

丹参川芎嗪注射液联合替格瑞洛用药时机对急性心肌梗死治疗效果的影响研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年7期
页码:
866-870
栏目:
药物与临床
出版日期:
2020-07-05

文章信息/Info

Title:
The timing of salviae miltiorrhizae and ligustrazine hydrochloride injection combined with ticagrelor on therapeutic effect of acute myocardial infarction
作者:
惠权斌1; 陈永刚2△; 陈 盼3
1.陕西省宝鸡市人民医院药剂科(宝鸡 721000); 2.陕西省永寿县人民医院心血管内科(咸阳 713400)；3.陕西省宝鸡市人民医院疾病预防控制科(宝鸡 721000)
Author(s):
HUI Quanbin; CHEN Yonggang; CHEN Pan.
Department of Pharmacy,Baoji People's Hospital,Shaanxi province(Baoji 721000)
关键词:
丹参川芎嗪;  替格瑞洛;  用药时机;  急性心梗;  效果;  影响
Keywords:
Salviae miltiorrhizae and ligustrazine hydrochloride injection;  Ticagrelor;  Timing of administration;  Acute myocardial infarction;  Effect;  Influence
分类号:
R543.3
DOI:
DOI:10.3969/j.issn.10007377.2020.07.027
文献标志码:
A
摘要:
目的:探究丹参川芎嗪注射液联合替格瑞洛用药时机对急性心肌梗死患者的疗效。方法:选择91例行经皮冠状动脉介入(PCI)治疗的急性心梗患者为研究对象,按照其用药时机的不同区分为术前组(40例)和术后组(51例),其中术前组PCI术前即接受替格瑞洛治疗,术后组PCI术后应用替格瑞洛治疗,两组患者术前术后均接受丹参川芎嗪治疗,对比两组患者治疗效果、术后不同时间心功能情况,以及术前术后两组患者生化指标差异,最后随访两组患者术后不良事件发生率。结果:①术前组溶栓再通率、近期再梗死、严重心律失常、心力衰竭总发生率低于术后组(P<0.05); ②术前组患者术后1个月和3个月时左室射血分数(LVEF)高于术后组,左室舒张末期内径(LVEDD)低于术后组(P<0.05); ③术前组术后3个月肌酸激酶同工酶(CK-MB)和心肌钙蛋白(cTnT)水平低于术后组(P<0.05); ④术前组术后3个月不良事件发生率低于术后组(P<0.05)。结论:行PCI术前联合应用丹参川芎嗪和替格瑞洛可以有效提高治疗效果,改善急性心梗患者心肌功能,同时降低术后不良事件发生率。
Abstract:
Objective:To explore the effect of the timing of salviae miltiorrhizae and ligustrazine hydrochloride injection combined with ticagrelor on therapeutic effect of acute myocardial infarction. Methods:91 patients with acute myocardial infarction who were treated by PCI were selected as the research objects. According to the different time of administration,they were divided into preoperative group(40 cases)and postoperative group(51 cases). The patients in the preoperative group received ticagrelor before PCI,and the patients in the postoperative group ticagrelor tegrilol after PCI. the patients in two groups were treated with salviae miltiorrhizae and ligustrazine hydrochloride injection before and after PCI. The effect,cardiac function at different time after operation,and the biochemical indexes in the two groups were compared. The incidence of adverse events was followed up. Results:The total incidence of thrombolytic recanalization,short-term reinfarction,serious arrhythmia and heart failure in the preoperative group was lower than that in the postoperative group(P<0.05). The left ventricular ejection fraction(LVEF)in the preoperative group was higher than that in the postoperative group at 1 and 3 months after operation,and the left ventricular end diastolic diameter(LVEDD)was lower than that in the postoperative group(P<0.05). The levels of CK-MB and cTnT were lower than those in the postoperative group at 3 months after operation(P<0.05). The incidence of adverse events in the preoperative group was lower than that in the postoperative group at 3 months after operation(P<0.05). Conclusion:The combination of salviae miltiorrhizae and ligustrazine hydrochloride injection and ticagrelor before PCI can effectively improve the effect,improve the myocardial function of patients with acute myocardial infarction,and reduce the incidence of adverse events after operation.

参考文献/References:

[1] 董 莹,王增武,王 馨,等.中国中年人群超敏C反应蛋白与心血管事件、总死亡事件的关联研究[J].中华流行病学杂志,2018,39(4):428-432.
[2] 陈 飞,喻金彦,印媛君.急性心肌梗死的流行病学及危险因素研究进展[J].浙江临床医学,2016,18(10):1954-1956.
[3] 周发展,武 君,张春玲,等.替罗非班应用于急诊经皮冠状动脉介入治疗对急性心肌梗死患者心肌灌注和内皮功能的影响[J].中华危重症医学杂志:电子版,2016,9(1):3-8.
[4] 戴 敬,吕树铮,宋现涛,等.介入术后无复流现象的研究进展[J].心肺血管病杂志,2014,33(1):133-135.
[5] Heusch G,Gersh BJ.The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion:a continual challenge[J].European Heart Journal,2017,38(11):224.
[6] 雷晓敏,曹 蕊. 冠状动脉内注射硝普钠对行经皮冠状动脉介入术急性心肌梗死患者心血管事件及左室功能的影响研究[J]. 陕西医学杂志,2019,48(10):1323-1325.
[7] Smolderen KG,Spertus JA,Gosch K,et al.Depression treatment and health status outcomes in young patients with acute myocardial infarction:insights from the virgo study(variation in recovery:role of gender on outcomes of young AMI Patients)[J].Circulation,2017,135(18):1762.
[8] 何柳平,覃月秋,高 艳.二维斑点追踪技术对左西孟旦治疗老年急性失代偿心力衰竭患者的疗效评价[J].山东医药,2017,57(17):48-50.
[9] 方利华,胡守琪. 应激性高血糖对急性ST段抬高心肌梗死静脉溶栓疗效的影响[J]. 宁夏医学杂志,2014,36(11):1033-1035.
[10] 陈海霞,何子峰,王利军. 阿替普酶在急性心梗溶栓治疗中的临床效果分析[J]. 医学信息,2016,29(1):127-128.
[11] 李一德,佘颖芳,吴先明,等.N端B型钠尿肽前体和肌钙蛋白I比值鉴别1型和2型心肌梗死的诊断价值研究[J].中国急救复苏与灾害医学杂志,2019,14(12):1206-1208,1218.
[12] 侯爱珍,肖观清,张 豫,等. 高通量透析对同型半胱氨酸水平及主要心血管事件的影响[J]. 实用医学杂志,2017,33(10):1544-1547.
[13] 黄香龙,栾运慧,石贺元,等. 补阳还五汤对心肌梗死后患者心脏重塑及心功能的作用研究[J]. 陕西中医,2018,39(10):42-44.
[14] 李月平,刘宇扬,史冬梅,等. 胰岛素敏感性的改善对胰岛素抵抗患者择期冠状动脉介入治疗术后心血管事件的影响[J]. 心肺血管病杂志,2016,35(9):700-704.
[15] 王丹丹,时家义. 体重指数对老年高血压患者心血管事件的影响[J]. 中国现代医生,2016,54(6):37-39.
[16] 许书嘉. 清热活血法联合益气养阴法对AMI患者PCI术后心功能的影响及随访研究[D]. 广州:广州中医药大学,2016.
[17] 李桂芝. 探讨美托洛尔在急性心梗早期溶栓治疗中的疗效[J]. 中国保健营养,2016,26(11):233.
[18] 符丽珍,肖孟生. 阿托伐他汀联合丹参川芎嗪对冠心病心肌梗死患者介入治疗后血清胱抑素C、髓过氧化物酶的影响[J]. 现代中西医结合杂志,2016,25(19):2128-2130.
[19] 聂 琦,陶立轩,余承熙,等. 丹参对心肌细胞氧化损伤的保护机制[J]. 中华实验外科杂志,2016,33(11):2611.
[20] 李瑞芳,王红伟,朱世超,等. 川芎嗪对异丙肾上腺素诱导的小鼠急性心肌缺血的保护作用[J]. 中国临床药理学杂志,2016,32(4):340-342.
[21] 黄 煜,赵灵芳. 替格瑞洛与氯吡格雷对急性ST段抬高型心肌梗死的临床疗效对比研究[J]. 中国继续医学教育,2016,8(27):159-161.
[22] 叶 明,王喜福,贾 平,等. 替格瑞洛对急性非ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后的疗效观察与安全性分析[J]. 中华医学杂志,2017,97(43):3376-3379.
[23] 梁 茜,张健瑜,杨希立,等. 急性冠脉综合征合并糖尿病患者经皮冠脉介入术后替格瑞洛与氯吡格雷的疗效比较[J]. 中国医科大学学报,2016,45(2):145-149.
[24] 陈 艳. 急性冠状动脉综合征患者口服抗血小板治疗新进展[J]. 心血管病学进展,2016,37(5):476-481.

相似文献/References:

[1]张 玲,郭利军△.氢氯吡格雷与替格瑞洛在急性ST段抬高型心肌梗死合并2型糖尿病患者经皮冠状动脉介入治疗中的效果观察[J].陕西医学杂志,2020,49(10):1339.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.037]
　ZHANG Ling,GUO Lijun..Efficacy of hydroclopidogrel and ticagrelor in PCI in patients with acute ST-segment elevation myocardial infarction and type 2 diabetes mellitus[J].,2020,49(7):1339.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.037]
[2]渊 潭,李今朝.老年冠心病患者经皮冠状动脉介入术术后应用低剂量替格瑞洛的可行性及安全性研究[J].陕西医学杂志,2021,50(1):86.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.023]
　YUAN Tan,LI Jinzhao.Feasibility and safety of low dose ticagrelor after percutaneous coronary intervention in elderly patients with coronary heart disease[J].,2021,50(7):86.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.023]
[3]袁小晶,王 佳.替格瑞洛对脓毒血症小鼠高迁移率蛋白1及免疫功能的影响[J].陕西医学杂志,2022,51(7):783.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.003]
　YUAN Xiaojing,WANG Jia.Effect of ticagrelor on high mobility protein 1 and immune function in septic mice[J].,2022,51(7):783.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.003]
[4]王 敏,裴蕊慧,向宗兴.CYP2C19基因型检测对急性心肌梗死经皮冠状动脉介入术后抗血小板药物治疗的临床研究[J].陕西医学杂志,2024,(10):1402.[doi:DOI:10.3969/j.issn.1000-7377.2024.10.023]
　WANG Min,PEI Ruihui,XIANG Zongxing.Clinical study of CYP2C19 genotype detection for antiplatelet therapy after PCI in patients with acute myocardial infarction[J].,2024,(7):1402.[doi:DOI:10.3969/j.issn.1000-7377.2024.10.023]

更新日期/Last Update: 2020-07-28